# Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

> **NCT01480284** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 166 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** GSK548470 300 mg tablet
- **DRUG:** ETV 0.5 mg capsule

## Key facts

- **NCT ID:** NCT01480284
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-01
- **Final completion:** 2014-11
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2016-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480284, "Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01480284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*